National Comprehensive Cancer Network



NCCN Oncology Research Program (ORP)
NCCN Mirvetuximab Soravtansine-Preclinical Research Grant Opportunity – Submit by October 26, 2015
Study Proposal Submission-NCCN RMS
ORP Recent News
ORP Affiliate Research Consortium
ORP Scientific Publications
ORP for Industry
ORP Investigator Steering Committee
ORP Testimonials
Clinical Trials at NCCN Member Institutions
Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
ORP Grant History
Informed Consent Language Database
Points to Consider on the Best Practices for Biorepositories, Registries and Databases
NCCN Shared Resources (Members Only
ORP Disclosure Policy
Call for Abstracts: NCCN General Poster Session
NCCN Collaboration with the National Business Group on Health
NCCN Health Information Technology Licensees

NCCN Research & Business Resources

Guidelines for Cervical Cancer Screening Updated and Published

The NCCN Clinical Practice Guidelines in Oncology™ for Cervical Cancer Screening have been updated to v.1.2010. The updated NCCN Guidelines include a new section providing recommendations for women who have positive results for the HPV High Risk DNA test but negative cervical cytology screen/Pap smears.

The new section in the updated NCCN Guidelines provides guidance for women 30 years and older who receive a positive result using the HPV High Risk DNA test but have a negative cervical cytology/Pap smear. Their options may include either 1) have the more specific HPV 16/18 DNA test, or 2) proceed directly to colposcopy. A colposcopy, where the cervix is viewed through a long focal-length microscope, is the primary method for evaluating women with abnormal cervical cytologies.